M de Ridder1, A J M Balm2, R J Baatenburg de Jong3, C H J Terhaard4, R P Takes5, M Slingerland6, E Dik7, R J E Sedee8, J G A M de Visscher9, H Bouman10, S M Willems11, M W Wouters12, L E Smeele2, B A C van Dijk13. 1. Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Head and Neck Surgery, Amsterdam, The Netherlands. Electronic address: m.d.ridder@nki.nl. 2. Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Head and Neck Surgery, Amsterdam, The Netherlands; Academic Medical Center, Department of Maxillo-facial Surgery, Amsterdam, The Netherlands. 3. Erasmus Medical Center, Department of Otorhinolaryngology, Rotterdam, The Netherlands. 4. University Medical Center Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands. 5. Radboud University Medical Center, Department of Otorhinolaryngology, Nijmegen, The Netherlands. 6. Leiden University Medical Center, Department of Medical Oncology, Leiden, The Netherlands. 7. Maastricht University Medical Center, Department of Cranio-maxillofacial Surgery Maastricht, The Netherlands. 8. Medical Center Haaglanden, Department of Otorhinolaryngology, Den Haag, The Netherlands. 9. Medical Center Leeuwarden, Department of Maxillo-facial Surgery, Leeuwarden, The Netherlands. 10. Rijnstate Hospital, Department of Otorhinolaryngology, Arnhem, The Netherlands. 11. Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands; The Nationwide Network and Registry of Histo- and Cytopathology in the Netherlands (PALGA), The Netherlands; University Medical Center Utrecht, Department of Pathology, Utrecht, The Netherlands. 12. Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Surgical Oncology, Amsterdam, The Netherlands. 13. Comprehensive Cancer Organization The Netherlands (IKNL), Department of Research, Utrecht, The Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands.
Abstract
BACKGROUND: To explore variation in numbers and treatment between hospitals that treat head and neck cancer (HNC) in the Netherlands. MATERIAL AND METHODS: Patient, tumor and treatment characteristics were collected from the Netherlands Cancer Registry, while histopathological features were obtained by linkage to the national pathology record register PALGA. Inter-hospital variation in volume, stage, treatment, pathologically confirmed loco-regional recurrence and overall survival rate was evaluated by tumor site. RESULTS: In total, 2094 newly diagnosed patients were included, ranging from 65 to 417 patients in participating hospitals treating HNC in 2008. Oral cavity cancer was mainly treated by surgery only, ranging from 46 to 82% per hospital, while the proportion of surgery with (chemo)radiotherapy ranged from 18 to 40%. Increasing age, male sex, and high stage were associated with a higher hazard of dying. In oropharynx cancer, the use of (chemo)radiotherapy varied from 31 to 82% between hospitals. We found an indication that higher volume was associated with a lower overall hazard of dying for the total group, but not by subsite. Low numbers, e.g. for salivary gland, nasopharynx, nasal cavity and paranasal sinus, did not permit all desired analyses. CONCLUSION: This study revealed significant interhospital variation in numbers and treatment of especially oropharyngeal and oral cavity cancer. This study is limited because we had to rely on data recorded in the past for a different purpose. To understand whether this variation is unwanted, future research should be based on prospectively collected data, including detailed information on recurrences, additional case-mix information and cause of death.
BACKGROUND: To explore variation in numbers and treatment between hospitals that treat head and neck cancer (HNC) in the Netherlands. MATERIAL AND METHODS:Patient, tumor and treatment characteristics were collected from the Netherlands Cancer Registry, while histopathological features were obtained by linkage to the national pathology record register PALGA. Inter-hospital variation in volume, stage, treatment, pathologically confirmed loco-regional recurrence and overall survival rate was evaluated by tumor site. RESULTS: In total, 2094 newly diagnosed patients were included, ranging from 65 to 417 patients in participating hospitals treating HNC in 2008. Oral cavity cancer was mainly treated by surgery only, ranging from 46 to 82% per hospital, while the proportion of surgery with (chemo)radiotherapy ranged from 18 to 40%. Increasing age, male sex, and high stage were associated with a higher hazard of dying. In oropharynx cancer, the use of (chemo)radiotherapy varied from 31 to 82% between hospitals. We found an indication that higher volume was associated with a lower overall hazard of dying for the total group, but not by subsite. Low numbers, e.g. for salivary gland, nasopharynx, nasal cavity and paranasal sinus, did not permit all desired analyses. CONCLUSION: This study revealed significant interhospital variation in numbers and treatment of especially oropharyngeal and oral cavity cancer. This study is limited because we had to rely on data recorded in the past for a different purpose. To understand whether this variation is unwanted, future research should be based on prospectively collected data, including detailed information on recurrences, additional case-mix information and cause of death.
Authors: Jason Siegel; Michael A Pizzi; J Brent Peel; David Alejos; Nnenne Mbabuike; Benjamin L Brown; David Hodge; W David Freeman Journal: Curr Cardiol Rep Date: 2017-08 Impact factor: 2.931
Authors: Lidia S van Huizen; Pieter Dijkstra; Gyorgy B Halmos; Johanna G M van den Hoek; Klaas T van der Laan; Oda B Wijers; Kees Ahaus; Jan G A M de Visscher; Jan Roodenburg Journal: BMJ Open Date: 2019-11-07 Impact factor: 2.692
Authors: Gijs Geleijnse; RuRu Chun-Ju Chiang; Melle Sieswerda; Melinda Schuurman; K C Lee; Johan van Soest; Andre Dekker; Wen-Chung Lee; Xander A A M Verbeek Journal: Sci Rep Date: 2020-11-25 Impact factor: 4.379
Authors: Lidia S van Huizen; Pieter U Dijkstra; Patrick H J Hemmer; Boudewijn van Etten; Carlijn I Buis; Linde Olsder; Frederike G I van Vilsteren; Kees C T B Ahaus; Jan L N Roodenburg Journal: Int J Integr Care Date: 2021-02-25 Impact factor: 5.120
Authors: Robert P Takes; Gyorgy B Halmos; John A Ridge; Paolo Bossi; Matthias A W Merkx; Alessandra Rinaldo; Alvaro Sanabria; Ludi E Smeele; Antti A Mäkitie; Alfio Ferlito Journal: Curr Oncol Rep Date: 2020-07-10 Impact factor: 5.075
Authors: Luiz Paulo Kowalski; Max Moura de Oliveira; Rossana Veronica Mendoza Lopez; Diego Rodrigues Mendonça E Silva; Mauro Kazuo Ikeda; Maria Paula Curado Journal: Clinics (Sao Paulo) Date: 2020-04-06 Impact factor: 2.365
Authors: Sam T H Reerds; Adriana C H Van Engen-Van Grunsven; Frank J A van den Hoogen; Robert P Takes; Henri A M Marres; Jimmie Honings Journal: Cancer Cytopathol Date: 2021-04-28 Impact factor: 5.284